NIH Names Dr Philip E. Bourne First Associate Director for Data Science
National Institutes of Health Director Francis S. Collins, MD, PhD, has announced the selection of Philip E. Bourne, PhD, as the first permanent Associate Director for Data Science (ADDS). Dr Bourne is expected to join the NIH in early 2014.
“Phil will lead an NIH-wide priority initiative to take better advantage of the exponential growth of biomedical research datasets, which is an area of critical importance to biomedical research. The era of ‘Big Data’ has arrived, and it is vital that the NIH play a major role in co-ordinating access to and analysis of many different data types that make up this revolution in biological information,” said Collins.
Dr Bourne comes to the NIH from the University of California San Diego, where he is the Associate Vice Chancellor for Innovation and Industry Alliances of the Office of Research Affairs and a Professor in the Department of Pharmacology and the Skaggs School of Pharmacy and Pharmaceutical Sciences. He also is the Associate Director of the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank. Dr Bourne was trained as a physical chemist and obtained his PhD from The Flinders University in South Australia.
Dr Bourne’s professional interests focus on relevant biological and educational outcomes derived from computation and scholarly communication. This work involves the use of algorithms, text mining, machine learning, metalanguages, biological databases, and visualisation applied to problems in systems pharmacology, evolution, cell signaling, apoptosis, immunology and scientific dissemination. He has published more than 300 papers and five books. One area to which he is extremely committed is to furthering the free dissemination of science through new models of publishing and better integration and subsequent dissemination of data and results.
Collins added: “I also must recognise and thank Dr Eric Green, who served as the Acting ADDS since I announced the search to fill this new position. His willingness to take on this challenging role in its inception, and to get the ball rolling on the enormous tasks that accompany this high-priority initiative, is sincerely appreciated. Eric is certain to remain a tremendous source of knowledge and support as Phil continues the NIH’s effort to manage ‘Big Data’.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance